French teen is 12-years in remission

Organisation: Position: Deadline Date: Location:

An 18-year-old French woman is in remission from HIV – despite not having taken any drugs against the virus for 12 years. BBC News reports that doctors have presented the details of her case at an International Aids Society (IAS) conference in Vancouver – the world’s first report of long-term remission from HIV in a child. Experts say in the report that big studies are needed to determine why some patients can continue to control the virus after stopping treatment.

The woman was born in 1996, and was passed HIV by her mother – either towards the end of the pregnancy or during childbirth. Aged three months, she was given four antiretroviral drugs. But her family decided to stop the treatment when she was almost six years old. Twelve years later, the virus levels in her bloodstream are too low to be measured – although doctors have cautioned that this could change.

Dr Asier Saez-Cirion, from the Institute Pasteur, in Paris, said: “It’s likely that this girl has been in virological remission for so long because she received a combination of antiretrovirals very soon after infection. With this first, highly documented case of this young woman, we provide the proof of concept that long-term remission is possible in children, as in adults. However, these cases are still very rare.”

The report says two years ago, a young girl in America – who became known as the “Mississippi baby” – appeared to be free of HIV. But her remission lasted for just over two years after drug treatment was stopped.

Saez-Cirion has also led research into a group of 14 adult patients known as the Visconti cohort. They also had no signs of the virus re-emerging, despite stopping medicine. One of the patients has had the virus under control for more than 13 years.

Professor Sharon Lewin, from the University of Melbourne, in Australia, said: “The French teenager case provides strong evidence yet again of the powerful benefits of starting anti-HIV treatment as early as possible. Lewin added: “Important though this case is, I strongly believe that to advance our efforts towards finding a cure for HIV, we need large prospective studies that can nail down who might be able to safely stop anti-viral therapy and keep the virus under control. A single case report is unable to do that.”

“We need to identify a robust test to measure very low levels of virus or find a better way to predict this idea of post-treatment control. If we had such a test, this would really help move clinical trials in the HIV cure field forward,” she added.

The French virologist Francoise Barre-Sinoussi, who won the Nobel Prize for identifying HIV, also backed the idea of large studies. She is quoted in the report as saying: “We need to try to find other such cases – and find out their markers, to see whether we can predict remission.

 

There are people known as “elite controllers” whose immune systems appear to keep the virus at bay, but according to Asier Sáez-Cirión, the Frenchwoman does not have the genetic factors associated with those. “Most likely she has been in virological remission for so long because she received a combination of antiretrovirals very soon after infection.”

The Guardian reports that Sáez-Cirión said there were 580 people in France who contracted HIV as babies, of whom about 100 were given drug treatment within the first six months of life. Of those, 15 stopped treatment, but the virus rebounded within weeks or months in 13 of them. Of the two remaining, one lasted for three years without needing drugs and the other is the young woman who has been off treatment for 12 years.

Full BBC News report
Full report in The Guardian


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.